NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,578.30 +102.38 (+0.55%) CRUDE OIL
78.86 +0.38 (+0.48%) GOLD FUTURES
2,332.70 +1.50 (+0.06%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,380.47 -585.43 (-1.15%)
DNLI May 2024 22.500 call
| Previous close | 0.1100 |
| Open | 0.1100 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 22.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.1100 - 0.1100 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
GlobeNewswireDenali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, which
Simply Wall St.Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.74 Denali...
ZacksWhy Denali Therapeutics (DNLI) Stock Might be a Great Pick
Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
